Ignite Creation Date:
2024-05-06 @ 2:41 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04394663
Status:
RECRUITING
Last Update Posted:
2022-08-26
First Post:
2020-05-14
Brief Title:
High Dose Oral Omeprazole in High Risk UGIB
Sponsor:
King Chulalongkorn Memorial Hospital
Organization:
King Chulalongkorn Memorial Hospital
Study Overview
Official Title:
High Dose Oral Omeprazole Versus Standard Continuous Intravenous Pantoprazole in Patient With Peptic Ulcer Bleeding and Undergo Successful Therapeutic Endoscopy Non-inferiority Randomized Controlled Trial
Status:
RECRUITING
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Peptic ulcer bleeding is the most common etiology in upper gastrointestinal bleeding all over the world After endoscopic treatment proton pump inhibitor PPI is recommended to prevent re-bleeding Intravenous PPI is recommended as a standard treatmentIn the past there were many trials showing the efficacy of high-dose oral PPI after endoscopic hemostasis but most were industrial sponsor which assessing an expensive PPI Moreover the number of patients in those studies were insufficient to confirm a non-inferiority outcome in term of rebleeding by using oral PPI This study will evaluate a high-dose local-made PPI omeprazole in peptic ulcer treatment after successful endoscopic hemostasis compared to standard IV PPI continuous drip
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None